Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inbox Gmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscription Click this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Further Reading from MarketBeat Why Boston Scientific's Big Dip Could Be a Bigger OpportunitySubmitted by Nathan Reiff. Publication Date: 3/24/2026. 
Key Points - Boston Scientific shares are down over 25% year-to-date after investors may have been disappointed by the company's 2026 sales guidance.
- Still, there are many positives that could entice investors keen to buy the dip, including strong free cash flow growth and the prospect of access to new markets with the impending completion of the Penumbra acquisition.
- A potential major catalyst for growth is the Champion trial, which could significantly increase the addressable patient pool of Boston Scientific's Watchman line.
- Special Report: Elon Musk: This Could Turn $100 into $100,000
Medical device manufacturer Boston Scientific Corp. (NYSE: BSX) has had a rough start to the year: shares are down about 26% year-to-date (YTD) and nearly a third over the past 12 months. Yet the company's fundamentals show recent strength — adjusted earnings per share (EPS) were $0.80 for the most recent quarter, $0.02 above consensus — and several product lines are growing rapidly. In particular, Boston Scientific's electrophysiology (EP) segment, and its Watchman line, have posted strong growth and appear positioned to keep delivering. The company is also expected to report results from its Champion-AF trial by the end of March, which could materially expand Watchman's addressable patient pool. That combination has some investors tempted to buy the dip in BSX, though it's important to remember why shares fell and what risks remain. Is the Boston Scientific Dip Justified? After nearly five decades on Wall Street, Louis Navellier says a major currency shift is already underway - and the wealthiest Americans, including Musk, Zuckerberg, and Ellison, are quietly moving money out of dollars and into a different type of asset entirely. It's not bitcoin or any other crypto. Navellier has identified 7 companies he believes are positioned at the center of this trend - the last time he spotted a setup like this, Nvidia climbed as high as 10,000%. Watch Navellier's urgent briefing and get all 7 company names Shares of BSX sold off after the company's February earnings release, despite revenue rising roughly 16% year over year and adjusted EPS beating expectations. Free cash flow improved markedly as well, climbing about 38% year over year to roughly $3.7 billion. The selloff appears tied largely to management's 2026 organic revenue guidance of 10% to 11% growth, which is materially slower than 2025's roughly 20% full-year growth. Part of that moderation reflects the company's decision to discontinue certain Axios catheter products and other lines earlier this year; management estimates this will shave about 150 basis points off early-2026 growth. Still, much of Boston Scientific's business is intact and expanding. Management expects another year of rising free cash flow — about $4.2 billion anticipated in 2026 — along with continued operating-margin improvement and other efficiency gains. The Champion Trial Could Be a Catalyst for Reversal A positive Champion trial could help reverse BSX's recent slide. The trial compares Boston Scientific's Watchman left atrial appendage occlusion device against oral anticoagulation for stroke prevention. If Champion demonstrates favorable outcomes, the addressable patient pool for Watchman could expand dramatically — potentially up to 20 million people, roughly four times current estimates. That kind of expansion would be meaningfully accretive over multiple years, creating millions of additional potential patients and supporting global sales growth for the device. Another potential growth driver is Boston Scientific's planned acquisition of neurovascular device maker Penumbra (NYSE: PEN). The $14.5 billion deal would give Boston Scientific entry into the mechanical thrombectomy market, where it currently has no presence. The purchase is partially financed by a $6 billion term loan secured in late February, which adds leverage near term but may be manageable given Boston Scientific's improving free cash flow and underlying business strength. Risks and Analyst Perspectives Are Worth Keeping in Mind A negative Champion result would be a major headwind: it could undercut the thesis for accelerating Watchman sales and make the company's 2026 revenue guidance harder to achieve. Other execution risks tied to integration of Penumbra and management of increased leverage also merit attention. That said, Wall Street remains broadly bullish. Of 25 analyst ratings, 23 are Buys and two are Holds. Several firms — including Stifel Nicolaus, Jefferies, and Truist Financial — reaffirmed Buy ratings in March, though some have trimmed price targets even while maintaining their Buy stance. The consensus price target of $106.27 implies over 50% upside from current levels, which helps explain the optimism despite short-term uncertainty. | 
Post a Comment
Post a Comment